Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

1.

Mechanisms promoting physiological cells progression into tumorigenesis.

Korbut E, Ptak-Belowska A, Brzozowski T.

J Physiol Pharmacol. 2012 Dec;63(6):565-70.

PMID:
23388471
[PubMed - indexed for MEDLINE]
Free Article
2.

Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.

Zhu C, Cheng KW, Ouyang N, Huang L, Sun Y, Constantinides P, Rigas B.

Stem Cells. 2012 Oct;30(10):2065-75. doi: 10.1002/stem.1139.

PMID:
22653497
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Tackling the cancer stem cells - what challenges do they pose?

Pattabiraman DR, Weinberg RA.

Nat Rev Drug Discov. 2014 Jul;13(7):497-512. doi: 10.1038/nrd4253.

PMID:
24981363
[PubMed - indexed for MEDLINE]
4.

MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics.

Xia H, Hui KM.

Cancer Gene Ther. 2012 Nov;19(11):723-30. doi: 10.1038/cgt.2012.58. Epub 2012 Sep 14. Review.

PMID:
22975591
[PubMed - indexed for MEDLINE]
5.

c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.

Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.

Oncogene. 2013 May 30;32(22):2767-81. doi: 10.1038/onc.2012.290. Epub 2012 Jul 16.

PMID:
22797058
[PubMed - indexed for MEDLINE]
6.

Emerging roles for modulation of microRNA signatures in cancer chemoprevention.

Neelakandan K, Babu P, Nair S.

Curr Cancer Drug Targets. 2012 Jul;12(6):716-40. Review.

PMID:
22515522
[PubMed - indexed for MEDLINE]
7.

Cancer stem cells: how can we target them?

Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ.

Curr Med Chem. 2008;15(30):3171-84. Review.

PMID:
19075661
[PubMed - indexed for MEDLINE]
8.

Cancer stem cells: the development of new cancer therapeutics.

Scatena R, Bottoni P, Pontoglio A, Giardina B.

Expert Opin Biol Ther. 2011 Jul;11(7):875-92. doi: 10.1517/14712598.2011.573780. Epub 2011 Mar 30. Review.

PMID:
21463158
[PubMed - indexed for MEDLINE]
9.

Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.

Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Review.

PMID:
18718806
[PubMed - indexed for MEDLINE]
10.

Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia.

Marie-Egyptienne DT, Lohse I, Hill RP.

Cancer Lett. 2013 Nov 28;341(1):63-72. doi: 10.1016/j.canlet.2012.11.019. Epub 2012 Nov 28. Review.

PMID:
23200673
[PubMed - indexed for MEDLINE]
11.

Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment.

Jiang H, Lin X, Liu Y, Gong W, Ma X, Yu Y, Xie Y, Sun X, Feng Y, Janzen V, Chen T.

Mol Med. 2012 Oct 24;18:1197-208. doi: 10.2119/molmed.2012.00075.

PMID:
22801793
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cancer stem cells and their potential implications for the treatment of solid tumors.

Grotenhuis BA, Wijnhoven BP, van Lanschot JJ.

J Surg Oncol. 2012 Aug 1;106(2):209-15. doi: 10.1002/jso.23069. Epub 2012 Feb 27. Review.

PMID:
22371125
[PubMed - indexed for MEDLINE]
13.

EMT in breast cancer stem cell generation.

Ansieau S.

Cancer Lett. 2013 Sep 10;338(1):63-8. doi: 10.1016/j.canlet.2012.05.014. Epub 2012 May 22. Review.

PMID:
22634497
[PubMed - indexed for MEDLINE]
14.

Cancer stem cells.

Yu Z, Pestell TG, Lisanti MP, Pestell RG.

Int J Biochem Cell Biol. 2012 Dec;44(12):2144-51. doi: 10.1016/j.biocel.2012.08.022. Epub 2012 Sep 2. Review.

PMID:
22981632
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Drug discovery approaches to target Wnt signaling in cancer stem cells.

Curtin JC, Lorenzi MV.

Oncotarget. 2010 Nov;1(7):552-66. Review.

PMID:
21317452
[PubMed - indexed for MEDLINE]
Free Article
16.

Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway.

Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W, Qi X, Pei Y, Zhu X, Zhao Z, Yang L.

J Exp Clin Cancer Res. 2011 Oct 28;30:103. doi: 10.1186/1756-9966-30-103.

PMID:
22032476
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Colorectal cancer stem cells.

Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG.

Stem Cells. 2012 Mar;30(3):363-71. doi: 10.1002/stem.1031. Review.

PMID:
22232074
[PubMed - indexed for MEDLINE]
Free Article
18.

Cancer stem cells in solid tumors.

Ailles LE, Weissman IL.

Curr Opin Biotechnol. 2007 Oct;18(5):460-6. Review.

PMID:
18023337
[PubMed - indexed for MEDLINE]
19.

Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.

Shigdar S, Lin J, Li Y, Yang CJ, Wei M, Zhus Y, Liu H, Duan W.

Ther Deliv. 2012 Feb;3(2):227-44. Review.

PMID:
22834199
[PubMed - indexed for MEDLINE]
20.

Role of the tissue factor pathway in the biology of tumor initiating cells.

Garnier D, Milsom C, Magnus N, Meehan B, Weitz J, Yu J, Rak J.

Thromb Res. 2010 Apr;125 Suppl 2:S44-50. doi: 10.1016/S0049-3848(10)70012-8.

PMID:
20434004
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk